Olema Pharmaceuticals Reports Tomorrow, Where Another Quarter of Losses Counts as Clinical Progress

Olema Pharmaceuticals (NASDAQ: OLMA) reports first-quarter 2026 earnings on May 12, 2026, with analysts expecting a loss of $0.52 per share. The clinical-stage biotech faces a critical juncture as investors assess progress on its lead candidate OP-1250, an oral complete estrogen receptor antagonist and degrader targeting hormone receptor-positive breast cancer, while the company navigates a challenging technical backdrop and mounting losses. With Wall Street maintaining overwhelmingly bullish price targets despite deteriorating near-term sentiment signals, this report will test whether clinical momentum can offset cash burn concerns and reverse the stock's recent slide below key moving averages.

Part 1: Earnings Preview

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for women's cancers, with its lead asset OP-1250 currently in multiple Phase 1/2 trials for hormone receptor-positive breast cancer. The company's strategy centers on demonstrating OP-1250's potential as both a monotherapy and in combination regimens, positioning it as a differentiated player in the competitive ER-targeted oncology landscape.

OLMA reports Q1 2026 results on May 12, 2026, with the consensus calling for a loss of $0.52 per share. The company most recently reported Q4 2025 earnings of -$0.50 per share on March 16, 2026, narrowly beating the -$0.51 estimate. Compared to the year-ago quarter when OLMA posted -$0.36 per share, the current estimate implies a 44% deterioration in losses, reflecting accelerated R&D spending as clinical programs advance. Revenue estimates are not available, consistent with OLMA's pre-commercial status.

Three key themes define this earnings story:

Clinical Progress and Trial Enrollment: Investors will scrutinize updates on OP-1250's Phase 1/2 trials, particularly enrollment rates, safety profiles, and any preliminary efficacy signals. With multiple studies running concurrently—both monotherapy and combination arms—management commentary on patient response rates and adverse event profiles will be critical. Any data readouts or regulatory feedback could significantly move the stock, as clinical validation remains the primary value driver for this pre-revenue biotech.

Cash Runway and Burn Rate: With losses widening year-over-year and no product revenue, OLMA's cash position and quarterly burn rate take center stage. Analysts will parse balance sheet metrics to assess how long current capital can fund operations without additional financing. Management's guidance on R&D spending trajectory and potential partnership discussions will signal whether dilutive capital raises loom on the horizon, a key concern given the stock's recent weakness.

Competitive Positioning in ER-Targeted Therapies: The breast cancer treatment landscape is crowded with established players and emerging competitors. Investors want clarity on how OP-1250's complete ER antagonist mechanism differentiates from existing selective ER degraders (SERDs) and whether the company can carve out a meaningful market position. Any commentary on potential combination partners, biomarker strategies, or head-to-head comparisons will shape the investment thesis.

Leading analysts remain constructive despite near-term headwinds. The 12 Strong Buy ratings and $43 mean price target (189% upside from current levels) reflect confidence in OP-1250's clinical potential, though the lack of recent upgrades and deteriorating technical signals suggest some caution has crept into the narrative. Analysts will be listening for management's confidence in hitting clinical milestones and maintaining financial flexibility through key data catalysts.

Part 2: Historical Earnings Performance

Olema Pharmaceuticals has delivered a mixed earnings track record over the past four quarters, with two beats and two misses against analyst estimates. The company's most recent quarter (Q4 2025) showed a loss of $0.50 per share, beating the -$0.51 consensus by 1.96%—a modest outperformance that followed two consecutive misses.

Looking at the pattern, OLMA's largest surprise came in Q1 2025 when it reported -$0.36 per share against a -$0.49 estimate, a +26.53% beat that demonstrated better-than-expected expense management. However, the subsequent two quarters disappointed: Q2 2025 missed by -18.60% (reporting -$0.51 vs. -$0.43 expected) and Q3 2025 missed by -11.36% (reporting -$0.49 vs. -$0.44 expected). The Q4 beat represented a return to form, though the magnitude was far smaller than the Q1 outperformance.

The year-over-year trend shows accelerating losses, with Q4 2025's -$0.50 representing a 39% deterioration from Q4 2024's -$0.36. This widening loss profile reflects the company's clinical-stage status and ramping R&D investments as OP-1250 trials progress. The inconsistent surprise pattern—alternating between significant beats and meaningful misses—suggests forecasting difficulty around quarterly burn rates, likely tied to the timing of clinical trial expenses and enrollment milestones. Investors should expect continued volatility in quarterly results until the company achieves more predictable operating rhythms or reaches commercialization.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Olema Pharmaceuticals typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results drop, while Day +1 captures the market's first full reaction to the actual numbers.

OLMA exhibits significant post-earnings volatility, with an average absolute Day 0 move of 5.06% and Day +1 move of 6.96%. The most recent earnings (March 2026) triggered the largest reaction in the dataset: a +12.85% Day 0 surge followed by a -9.31% Day +1 reversal, demonstrating how quickly sentiment can shift on clinical-stage biotech results.

The directional pattern is inconsistent, with Day 0 moves ranging from -9.28% (November 2024) to +12.85% (March 2026), and Day +1 moves spanning -9.90% (August 2024) to +16.19% (August 2025). Notably, the Day +1 average range of 13.69% is nearly double the Day 0 average range of 7.34%, indicating that the market's full digestion of earnings details—including management commentary on clinical progress and cash runway—often produces more dramatic moves than the initial reaction. Investors should prepare for potential two-day swings exceeding 10% in either direction, with the stock's pre-revenue status amplifying sensitivity to any clinical updates or cash burn guidance embedded in the release.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.29% expected move through the May 15 expiration, which sits below both the average Day 0 move of 5.06% and well below the average Day +1 move of 6.96%. This suggests options traders may be underpricing the stock's historical earnings volatility, potentially creating opportunity for volatility strategies, though the 238% implied volatility indicates elevated premium costs heading into the event.

Part 3: What Analysts Are Saying

Wall Street maintains overwhelmingly bullish sentiment on Olema Pharmaceuticals, with 12 Strong Buy ratings, 0 Moderate Buys, 2 Holds, and zero sell ratings among the 14 analysts covering the stock. The average recommendation of 4.71 (on a 5-point scale) reflects strong conviction in the company's clinical pipeline, while the mean price target of $43.00 implies 189% upside from the current $14.86 price. Price target estimates range from a low of $27.00 to a high of $62.00, with even the most conservative target suggesting 82% upside.

Analyst sentiment has remained unchanged over the past month, with the Strong Buy count holding steady at 12 and the Hold count at 2. This stability suggests the analyst community is maintaining conviction despite the stock's recent technical weakness, likely viewing current levels as an attractive entry point ahead of potential clinical catalysts. The lack of any sell ratings is particularly notable given OLMA's pre-revenue status and widening losses, indicating analysts believe the risk-reward profile remains favorable as OP-1250 progresses through trials.

The $43 consensus target represents a significant premium to current trading levels, implying analysts expect clinical data readouts or partnership announcements to serve as major revaluation catalysts. However, the wide target range—from $27 to $62—reflects meaningful uncertainty around the probability and timing of OP-1250's commercial success. The 2 Hold ratings likely represent more conservative views on execution risk or concerns about the cash runway required to reach key milestones, though even these analysts haven't turned outright bearish. For investors, the unanimous absence of sell ratings and the 86% Strong Buy concentration signal that Wall Street views any near-term weakness as a buying opportunity, provided clinical progress continues on track.

Part 4: Technical Picture

Olema Pharmaceuticals enters earnings in a deteriorating technical position, with the Barchart Technical Opinion showing an 88% Sell signal—a sharp weakening from 72% Sell one week ago and 24% Sell one month ago. This rapid deterioration reflects mounting downside momentum as the stock has broken below multiple support levels heading into the May 12 report.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downside pressure and negative momentum heading into earnings
• Medium-term (100% Sell): Equally bearish intermediate-term reading suggests the weakness extends beyond just recent sessions and reflects a broader trend reversal
• Long-term (50% Sell): Moderate sell signal shows the longer-term trend has also turned negative, though with less conviction than shorter timeframes

Trend Characteristics: The Weak Strengthening characterization indicates the sell signal is gaining intensity but hasn't yet reached maximum conviction, suggesting further downside risk remains if earnings disappoint or fail to provide a strong catalyst.

The stock trades below its 5-day ($14.94), 20-day ($15.43), 50-day ($16.00), 100-day ($21.02), and 200-day ($16.18) moving averages, with only the 10-day average ($14.68) providing support. This configuration—where price sits below nearly all key moving averages—is a classic bearish setup, indicating sellers have controlled the tape across multiple timeframes. The 100-day average at $21.02 represents a particularly significant overhead resistance level, sitting 41% above current prices.

The technical setup heading into earnings is decidedly cautionary, with OLMA trapped below a dense cluster of resistance levels and all timeframe signals flashing red. The stock would need to reclaim the $15.43 20-day moving average to signal even a short-term stabilization, while a move back above the $16.00-$16.18 zone (50-day and 200-day averages) would be required to suggest a meaningful trend reversal. Given the Weak Strengthening sell signal and the stock's position below five of six key moving averages, the technical backdrop provides little cushion if earnings disappoint—but also sets up potential for an outsized rally if results and guidance exceed expectations, as the heavy short-term bearishness could fuel a sharp reversal on positive news. Traders should watch the $14.22-$15.50 implied move range as key battleground levels, with a break above $15.50 potentially triggering short covering into the 20-day average.